We are live on ! Find out more
BBC icon

Virtus Biotech Clinical Trials ETF
BBC

10 hedge funds and large institutions have $8.57M invested in Virtus Biotech Clinical Trials ETF in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

150% more funds holding

Funds holding: 4 → 10 (+6)

11% more capital invested

Capital invested by funds: $7.75M → $8.57M (+$825K)

Holders
10
Holders Change
+6
Holders Change %
+150%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$6.11M
2
LPL Financial
LPL Financial
California
+$581K
3
CS
Credit Suisse
Switzerland
+$436K
4
BAAM
Baker Avenue Asset Management
California
+$248K
5
Jane Street
Jane Street
New York
+$136K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$6.23M
2
VKH
Virtu KCG Holdings
New York
-$1.16M

BBC Hedge Fund Activity: Q1 2015 in Review

10 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2015, worth a combined $8.57M — up 11% from $7.75M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BBC positions and 2 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $6.11M. The largest seller was Deutsche Bank, exiting entirely with an estimated $6.23M sold.

  • 10 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2015, up from 4 in Q4 2014.
  • Funds reported $8.57M of Virtus Biotech Clinical Trials ETF stock for Q1 2015, up 11% quarter-over-quarter.
  • 8 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2015 and 2 closed out, a net change of +6 holders.
  • The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2015 was Goldman Sachs, an estimated $6.11M added.
  • The largest Virtus Biotech Clinical Trials ETF seller in Q1 2015 was Deutsche Bank, an estimated $6.23M sold.

Based on aggregated 13F filings for Q1 2015.